Abstract
In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Current Drug Discovery Technologies
Title:Network Pharmacology: Reigning in Drug Attrition?
Volume: 10 Issue: 2
Author(s): Osama M. Alian, Minjel Shah, Momin Mohammad and Ramzi M. Mohammad
Affiliation:
Keywords: Network pharmacology, drug attrition, systems biology, network medicine
Abstract: In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities) reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of disease, essentially reigning in the phenomenon of drug attrition.
Export Options
About this article
Cite this article as:
M. Alian Osama, Shah Minjel, Mohammad Momin and M. Mohammad Ramzi, Network Pharmacology: Reigning in Drug Attrition?, Current Drug Discovery Technologies 2013; 10 (2) . https://dx.doi.org/10.2174/1570163811310020008
DOI https://dx.doi.org/10.2174/1570163811310020008 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Mechanism and Pathophysiological Role of Polyamine Transport in Mammalian Mitochondria. Answer to Debated Questions
Mini-Reviews in Organic Chemistry Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Structural Modifications on CORM-3 Lead to Enhanced Anti-angiogenic Properties Against Triple-negative Breast Cancer Cells
Medicinal Chemistry pH-Sensitive PEGylated Liposomes Functionalized With a Fibronectin-Mimetic Peptide Show Enhanced Intracellular Delivery to Colon Cancer Cells
Current Pharmaceutical Biotechnology Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases
Current Drug Metabolism Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Fecal DNA Genotyping: A Non-invasive Approach to Characterize Mouse Models for Nutrigenomics Cancer Chemoprevention Studies
Current Pharmacogenomics and Personalized Medicine Trends in Nanotechnology Patents Applied to the Health Sector
Recent Patents on Nanotechnology Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Current Molecular Medicine Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers